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BACKGROUND In the setting of primary percutaneous coronary
intervention (PPCI), patients with a concurrent chronic total occlusion
(CTO) in a non-infarct related artery (IRA) were recently identiﬁed as a
high-risk subgroup. It is unclear whether ST-elevation myocardial
infarction (STEMI) patients with a CTO in a non-IRA should undergo
additional percutaneous coronary intervention of the chronic total
occlusion on top of optimal medical therapy shortly after PPCI.
Possible beneﬁcial effects include reduction in adverse left ventricular
remodeling and preservation of global left ventricular function and
improved long term clinical outcome.
METHODS The EXPLORE trial is a global randomized, prospective,
multicenter, two-arm trial with blinded evaluation of endpoints. A
total of 304 patients were included after successful PPCI for STEMI
with a concurrent CTO in a non-IRA and were randomized to either
elective PCI of the CTO within 7 days or standard medical treatment.
Primary endpoints are left ventricular ejection fraction and left ven-
tricular end-diastolic volume assessed by cardiac Magnetic Resonance
Imaging at four months, analyzed by an independent corelab. All
events underwent independent monitoring and were adjudicated by
an independent critical events committee. Furthermore, all angiog-
raphies were reviewed by an independent corelab.
RESULTS In total, 304 STEMI patients with a CTO were included from
07-11-2007 until 30-03-2015. Data is currently analyzed.
CONCLUSIONS The ongoing EXPLORE trial is the ﬁrst randomized
clinical trial powered to investigate whether recanalization of a chronic
total occlusion in a non-infarct related artery after primary percuta-
neous coronary intervention for ST-elevation myocardial infarction
results in a better preserved residual left ventricular ejection fraction,
reduced end-diastolic volume and enhanced clinical outcome.
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BACKGROUND A major determinant of mortality and morbidity is the
extent of myocardial necrosis after STEMI, and strategies to limit
infarct size may therefore improve prognosis. As recently demon-
strated in human studies, pressure-controlled intermittent coronary
sinus occlusion (PICSO) may enhance myocardial recovery in acute
myocardial infarction. Whether coronary sinus occlusion should be
established before reperfusion is unknown.
METHODS In a prospective, controlled study, 28 pigs undergoing 90 mi-
nutes of left anterior descending (LAD) coronary artery balloon occlusion
followed by reperfusion were randomly assigned to 3 groups: Early PICSO(starting 10 minutes prior to reperfusion, group A, n¼9), Late PICSO
(starting 30 minutes post reperfusion, group B, n¼10), or reperfusion only
(group C, n¼9). PICSO was administered in an automatic mode for 90 mi-
nutes after initiation. Mean PICSO quantity was deﬁned as the sum of the
coronary sinus pressuremodulation for all PICSO cycles. Infarct size (% left
ventricular mass), microvascular obstruction (MVO), and left ventricular
function were assessed by cardiac magnetic resonance imaging (MRI) on
day 5. VEGF receptor expression was assessed by immunohistochemistry
after sacriﬁce on day 5.
RESULTS The histologic andMRI groupmean values for percent infarct
sizewere numerically lowest in GroupAwhen compared to GroupB and
Group C, albeit not reaching signiﬁcance (13.5%5.8% vs. 16.6%3.6%
vs. 16.2%4.2% respectively, p¼0.31). The same was true for MVO
(3.2%3.5% vs. 6.4%7.7% vs. 8.8%7.1% respectively, p¼0.16).
However, left ventricular ejection fraction (LVEF) was greatest in the
Early PICSO group (61.07.0% vs. 50.29.8% vs. 52.37.3% respec-
tively, p¼0.02), as was wall thickening (49.715.0 vs. 33.715.1 vs.
39.57.0 respectively, p¼0.045). Compared to control, group A animals
had 3-fold greater expression ofVEGF-R1 in themyocardial zone remote
from the infarct (median [IQR] 19 [12-24] vs. 9 [6.8-11.5] vs. 5 [3.5-8]
respectively, p¼0.001). Group B animals had 2-fold greater expression
of VEGF-R2 in the border zone of the infarct compared to control (5 [3.5-
9], 14.5 [9.5-16], 6 [5-12.5], respectively). No safety issues were noted.
CONCLUSIONS PICSO was safely applied in a porcine model of LAD
infarction. MRI at day 5 showed greater LVEF, better wall thickening,
and trends toward smaller infarct size and MVO in animals treated
with early PICSO, suggesting a cardioprotective effect of PICSO. In
addition, PICSO resulted in an increased VEGF-R1 expression in the
remote zone and VEGF-R2 in the border zone indicating, increased
neo-angiogenic activity. Large trials are underway to demonstrate the
beneﬁts of PICSO in humans.
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BACKGROUND When performing percutaneous coronary interven-
tion (PCI) for long-diffuse lesions, the best revascularization strategy
remains unclear with options including treating most of the vessel
length as opposed to a focal approach. A common option is to create a
“full-metal jacket (FMJ)”. However, FMJ may preclude future surgical
revascularization and may be associated with higher events rates at
follow-up. The use of bioresorbable scaffolds (BRS) is therefore very
attractive by virtue of their full reabsorption 2 to 3 years after
implantation. We aimed to investigate the feasibility and updated
clinical outcomes following BRS implantation for very long lesions
(“full-plastic jacket”).
METHODS We analyzed consecutive patients who underwent PCI with
Absorb BRS (Abbott Vascular, Santa Clara, CA) between May 2012 and
April 2015. Procedural “full-plastic jacket” (FPJ) was deﬁned as a
continuous implantation of BRS with 60mm length or more. During the
study period, 290 lesions (196 patients) treated with BRS (total length<
60mm) and 35 lesions (35 patients) treated with FPJ were identiﬁed.
RESULTS Patients treated with FPJ had a higher prevalence of dia-
betes (40.0% vs. 22.4%, p¼0.03), chronic total occlusion (17.1% vs.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B54.5%, p¼0.01), and higher SYNTAX scores (23.513.0 vs. 16.19.5,
p<0.001) compared to those with control BRS group (total length <
60mm). The main target vessel in the FPJ group was the LAD (80.0%).
The incidence of periprocedural myocardial infarction (as deﬁned by a
creatinine kinase (CK) >2 times the upper limit of normal in addition
to a CK-MB elevation) was higher in the FPJ group (FPJ 16.1% vs.
control BRS group 8.8%: p¼0.20). The incidence of major adverse
cardiac events (deﬁned as a combination of all-cause death, follow-up
myocardial infarction and target vessel revascularization) tended to
be higher in the FPJ group (FPJ 15.8% vs. control BRS group 9.4%:
p¼0.35) at 1-year follow-up. Deﬁnite scaffold thrombosis was
observed in 1 patient who was treated with a FPJ and stopped clopi-
dogrel at 2 months after PCI. The incidence of target lesion revascu-
larization (per lesion) was signiﬁcantly higher in the FPJ group (FPJ
12.5% vs. control BRS group 5.0%: p¼0.01).
CONCLUSIONS The incidence of periprocedural MI and TLR was
higher in the FPJ group. FPJ treatment for diffuse long lesions appears
to be feasible taking into account the greater co-morbidity and lesion
complexity in this group.
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BACKGROUND The study has ascertained the long term beneﬁts of
coronary stenosis treatment with a bioresorbable scaffold eluting
everolimus.
METHODS In the ABSORB Cohort B multi-center, single arm trial, 45
patients (B1) and 56 patients (B2) underwent at different time points
serial quantitative coronary angiography (QCA), intra vascular ultra-
sound (IVUS) and optical coherence tomography (OCT). At 5 years 53
patients without Target Lesion Revascularization (TLR) were re-con-
sented to undergo a ﬁnal serial invasive imaging.
RESULTS Between 6 months/1 year and 5 years angiographic luminal
late loss (LLL) remained unchanged; B1 0.1419mm vs 0.130.33mm,
p¼0.7953, B2 0.230.28mm vs 0.180.32mm, p¼0.5685. When pa-
tients with a TLR were included LLL was 0.150.20 mm vs
0.150.24 mm, p¼0.8275 for B1 and 0.300.37 mm vs 0.320.48 mm,
p¼0.8204 for B2. For the entire cohort in-scaffold and in-segment
binary restenosis was 7.8% (5/64) and 12.5% (8/64), respectively. On
IVUS the minimum lumen area (MLA) of B1 decreased from
5.230.97 mm2 at 6 months to 4.891.81mm2 at 5 years (p¼0.04)
while it remained unchanged in B2 (4.950.91mm2 at 1 year,
4.841.28 mm2 at 5 years, p¼0.5). At 5 years the struts were no longer
discernable by OCT and IVUS. On OCT MLA in B1 decreased from
4.511.28mm2 at 6 months to 3.651.39mm2 at 5years (p¼0.01), while
it remained unchanged in B2 (4.351.09mm2 at 1 year, 4.121.38mm2
at 5 years, p¼0.24). In the entire Cohort B the 5-year Major Adverse
Cardiac Event (MACE) rate was 11.0% without any scaffold throm-
bosis, deﬁnite or probable.CONCLUSIONS At 5 years implantation of a bioresorbable scaffold
resulted in stable lumen dimensions, a low restenosis rate and a low
MACE rate.
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BACKGROUND Bioresorbable vascular scaffold (BVS) overlap is
frequent in long coronary lesions. Its impact into clinical outcomes is
unknown. We aims to compare the short and long-term clinical out-
comes between patients with overlap BVS implanted and those with
no-overlap BVS.
METHODS We analyzed the clinical outcomes of 1627 patients treated
with BVS in the Gauging coronary Healing with biOresorbable Scaf-
folding plaTforms in Europe (GHOST-EU) registry, according to im-
plantation of overlap scaffolds. Primary endpoint was patient oriented
composite endpoint (POCE) of: all-cause death, any myocardial
infarction (MI) and any percutaneous coronary intervention. Device
oriented composite endpoint (DOCE) of cardiac death, target-vessel
(TV) MI and TV-revascularization was also analyzed. Scaffold throm-
bosis, according to ARC deﬁnition, was also collected. Follow-up was
performed at 1 and 12 months.
RESULTS A total of 287 (17.6%) patients were treated with overlap
BVS. The remaining 1340 (82.4%) received BVS not overlap. The
overlap group had signiﬁcantly higher prevalence of diabetes melli-
tus, acute coronary syndrome, B2/C lesion type, SYNTAX score 22,
lesion length >34 mm, use of intracoronary imaging during implan-
tation, pre and post-dilatation, dual antiplatelet duration. At 1-year,
POCE was not different between the overlap vs. no-overlap groups
(13.6% vs. 14.6%, p ¼ 0.712), even after adjustment for the difference
between the two groups. The DOCE was also no different between the
two groups (5.6% vs. 5.8%, p¼0.540). Rate of scaffold thrombosis did
not differ either at 30 days (1.4% vs. 1.2%, p¼0.768) or at 1-year (2.1%
vs. 2.2%, p¼1.000)
CONCLUSIONS In “Real-world” clinical practice, BVS overlap does
not appear to have an impact on outcomes and in particular on scaf-
fold thrombosis, whose rate is not negligible.
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